• Notice of Update to Application Forms Package for PA-17-225 "Advancing the Science of Geriatric Palliative Care (R01)"
  (NOT-AG-17-009)
  National Institute on Aging
• Notice of Correction to PAR-17-128 "Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)"
  (NOT-CA-17-064)
  National Cancer Institute
• Notice of Correction to PAR-17-129 "Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01)"
  (NOT-CA-17-065)
  National Cancer Institute
• Notice of Change to Components of Participating Organizations for PAR-16-052: "Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21)"
  (NOT-DA-17-037)
  National Institute on Drug Abuse
• Notice of Change in the Expiration Date for PA-15-112 "Gene-Environment Interplay in Substance Use Disorders (R21)"
  (NOT-DA-17-039)
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
• Notice of Extension of Expiration Date for PAR-14-346 "NIDCR Clinical Trial or Biomarker Clinical Validation Study Planning Grant (R34)"
  (NOT-DE-17-009)
  National Institute of Dental and Craniofacial Research
• Notice to Extend the Expiration Date for RFA-HL-16-006 "Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01)"
  (NOT-HL-17-514)
  National Heart, Lung, and Blood Institute
• Notice to Extend the Expiration Date for RFA-HL-16-007 "Training Program for Institutions That Promote Diversity (T32)"
  (NOT-HL-17-515)
  National Heart, Lung, and Blood Institute
• Notice to Extend the Expiration Date for RFA-HL-16-008 "Short-Term Research Education Program to Increase Diversity in Health-Related Research (R25)"
  (NOT-HL-17-516)
  National Heart, Lung, and Blood Institute
• Notice of Availability of Administrative Supplements for Validation of Renewable Antibodies Generated by the Protein Capture Reagents Program
  (NOT-RM-17-022)
  NIH Roadmap Initiatives
• Request for Information (RFI): Challenges and Opportunities in Extracellular RNA Communication
  (NOT-RM-17-025)
  NIH Roadmap Initiatives, The Common Fund/Office of Strategic Coordination
• Reminder: Interagency Edison Requests for Extensions of Time to Retain Title to a Subject Invention or to File an Initial Patent Application under NIH Funding Agreements
  (NOT-OD-17-065)
  National Institutes of Health
• Revised NIAAA Data and Safety Monitoring Plan Guidelines
  (NOT-AA-17-004)
  National Institute on Alcohol Abuse and Alcoholism
• Administrative supplements to develop research on Alzheimer's disease and Alzheimer's-related dementias (ADRD)
  (NOT-AG-17-008)
  National Institute on Aging
• Notice of Intent to Publish a Funding Opportunity Announcement for NCCIH Natural Product Phase I-IIa Clinical Trials Phased Innovation Award (R61/R33)
  (NOT-AT-17-010)
  National Center for Complementary and Integrative Health
• Notice of Correction to Key Dates for PAR-16-202 "Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R01)"
  (NOT-CA-17-057)
  National Cancer Institute
- Request for Proposals (RFP) N01PC65003-74 "Surveillance, Epidemiology, and End Results (SEER) Program" (NOT-CA-17-058)
  National Cancer Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment (U01) (NOT-CA-17-059)
  National Cancer Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for Consortium on Translational Research in Early Detection of Liver Cancer (Clinical and Research Centers (U01)) (NOT-CA-17-060)
  National Cancer Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for the Coordinating Center for the Consortium of Translational Research in Early Detection of Liver Cancer (U24) (NOT-CA-17-061)
  National Cancer Institute
- Notice of Correction to PA-17-109, "Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21)" (NOT-CA-17-062)
  National Cancer Institute
- Notice of Change in the Expiration Date for PA-15-082 "Drug Abuse Prevention Intervention Research (R01)" (NOT-DA-17-034)
  National Institute on Drug Abuse
- Notice of Change in the Expiration Date for PA-15-080 Drug Abuse Prevention Intervention Research (R21) (NOT-DA-17-035)
  National Institute on Drug Abuse
- Notice of Change in the Expiration Date for PA-15-110 Gene-Environment Interplay in Substance Use Disorders (R01) (NOT-DA-17-038)
  National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism
- Notice of Change to the Award Budget Limit for PAR-16-148 "Limited Competition: Small Grant Program for NIDDK K01/K08/K23 Recipients (R03)" (NOT-DK-17-012)
  National Institute of Diabetes and Digestive and Kidney Diseases
- Announcement of 3-D Retina Organoid Challenge (3-D ROC) (NOT-EY-17-006)
  National Eye Institute
- Notice of Change in the Expiration Date for PAR-17-273: Genomic Community Resources (U24) (NOT-HG-17-005)
  National Human Genome Research Institute
- NHLBI Policy for Submission of Investigator-Initiated, Collaborative R01 Applications (NOT-HL-17-512)
  National Heart, Lung, and Blood Institute
- Notice of Change of Open Date for AHRQ Clinical Decision Support Funding Opportunity Announcements (FOAs): PA-17-260 and PA-17-261 (NOT-HS-17-016)
  Agency for Healthcare Research and Quality
- Notice of Change in Funds Available and Anticipated Number of Awards for PAR-16-299, "Detecting and Preventing Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R01)" (NOT-MH-17-029)
  National Institute of Mental Health
- Notice of Change in Funds Available and Anticipated Number of Awards for PAR-16-298, "Pilot Studies to Detect and Prevent Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R34)" (NOT-MH-17-030)
  National Institute of Mental Health
- Notice of NINR's Participation on PA-17-195 Notice Title, "Targeted Implementation Science to Achieve 90/90/90 Goals for HIV/AIDS Prevention and Treatment (R21)" (NOT-NR-17-021)
  National Institute of Nursing Research
- Notice of NINR's Participation on PA-17-181 Notice Title, "Innovations in HIV Testing, Adherence, and Retention to Optimize HIV Care Continuum Outcomes (R21)" (NOT-NR-17-023)
  National Institute of Nursing Research
- Notice of NINR's Participation on PAR-16-052 Notice Title, "Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21)" (NOT-NR-17-024)
  National Institute of Nursing Research
• Notice of Expiration of NIH/BD2K Participation in the Joint NSF/NIH Initiative on Quantitative Approaches to Biomedical Big Data (QuBBDD) [NOT-EB-16-008]
  (NOT-RM-17-012)
  NIH Roadmap Initiatives
• Notice of Intent to Publish a Funding Opportunity Announcement for National Metabolomics Data Repository (U2C)
  (NOT-RM-17-018)
  NIH Roadmap Initiatives
• Notice of Intent to Publish a Funding Opportunity Announcement for Metabolomic Data Analysis and Interpretation Tools (U01)
  (NOT-RM-17-019)
  NIH Roadmap Initiatives
• Notice of Intent to Publish a Funding Opportunity Announcement for Compound Identification Development Cores (CIDC) (U2C)
  (NOT-RM-17-020)
  NIH Roadmap Initiatives
• Notice of Intent to Publish a Funding Opportunity Announcement for Community Engagement and Program Coordination Center (CEPCC) (U2C)
  (NOT-RM-17-021)
  NIH Roadmap Initiatives
• Notice of Information Regarding the "Announcement of Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test Challenge Competition"
  (NOT-OD-17-063)
  National Institutes of Health
• NIH and FDA Release Protocol Template for Phase 2 and 3 IND/IDE Clinical Trials
  (NOT-OD-17-064)
  National Institutes of Health
• Notice of Information: Alignment Among the Disease Definitions Utilized to Govern Genetic and Genomic Data Sharing for Studies Involving Alzheimer's Disease
  (NOT-AG-17-007)
  National Institute on Aging, National Institute of Neurological Disorders and Stroke
• Notice of Intent to Publish a Funding Opportunity Announcement for NCCIH Natural Product Early Phase Clinical Trials (R33)
  (NOT-AT-17-011)
  National Center for Complementary and Integrative Health
• Notice of NCI's Participation on PA-17-226, Advancing the Science of Geriatric Palliative Care (R21)
  (NOT-CA-17-055)
  National Cancer Institute
• Notice of Correction to Key Dates for PAR-16-201 "Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R21)"
  (NOT-CA-17-056)
  National Cancer Institute
• Notice of Change in the Expiration Date for PAR-15-119 "NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12)"
  (NOT-DA-17-030)
  National Institute on Drug Abuse
• Notice of Change in the Expiration Date for PA-15-002 "Epidemiology of Drug Abuse (R03)"
  (NOT-DA-17-031)
  National Institute on Drug Abuse
• Notice of Change in the Expiration Date for PA-15-001 Epidemiology of Drug Abuse (R21)
  (NOT-DA-17-032)
  National Institute on Drug Abuse
• Notice of Change in the Expiration Date for PA-15-003 Epidemiology of Drug Abuse (R01)
  (NOT-DA-17-033)
  National Institute on Drug Abuse
• Notice of Change in the Expiration Date for PA-15-081 Drug Abuse Prevention Intervention Research (R03)
  (NOT-DA-17-036)
  National Institute on Drug Abuse
• Notice of Reissuance of the "Modeling of Infectious Disease Agent Study Research Projects (R01)" Funding Opportunity Announcement
  (NOT-GM-17-006)
  National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases
• Notice of Change in PAR-17-045 "Focused Technology Research and Development (R01)"
  (NOT-GM-17-007)
  National Institute of General Medical Sciences
• Notice of Change in PAR-17-046 "Exploratory Research for Technology Development (R21)"
  (NOT-GM-17-008)
  National Institute of General Medical Sciences

• Notice of Cancellation of Two Application Due Dates for NHLBI RFA-HL-17-015 "Bold New Bioengineering Methods and Approaches for Heart, Lung, Blood and Sleep Disorders and Diseases (R21)"
  (NOT-HL-17-511)
  National Heart, Lung, and Blood Institute

• Notice of Frequently Asked Questions for RFA-HL-18-020 Integrative Computational Biology for Analysis of NHLBI TOPMed Data (R01)
  (NOT-HL-17-513)
  National Heart, Lung, and Blood Institute

• Notice of Correction to PAR-17-179 "From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (U01)"
  (NOT-MH-17-021)
  National Institute of Mental Health

• Notice of Correction to PAR-17-176 "From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (Collaborative U01)"
  (NOT-MH-17-022)
  National Institute of Mental Health

• Notice of Change of the Components of Participating Organizations for RFA-RM-17-005 NIH Director's Pioneer Award Program (DP1)
  (NOT-RM-17-026)
  NIH Roadmap Initiatives, The Common Fund/Office of Strategic Coordination

• Notice of Change of the Components of Participating Organizations for RFA-RM-17-006 NIH Director's New Innovator Award Program (DP2)
  (NOT-RM-17-027)
  NIH Roadmap Initiatives

• Notice of Change of the Components of Participating Organizations for RFA-RM-17-007 NIH Director's Transformative Research Awards (R01)
  (NOT-RM-17-028)
  NIH Roadmap Initiatives

• Notice of Change of the Components of Participating Organizations for RFA-RM-17-008 NIH Director's Early Independence Awards (DP5)
  (NOT-RM-17-029)
  NIH Roadmap Initiatives

• Notice of NCATS Participation in RFA-HL-17-025 "Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (U54)"
  (NOT-TR-17-016)
  National Center for Advancing Translational Sciences

REQUEST FOR APPLICATIONS

• TITLE: Planning Grants for Clinical Trials of High Relevance to the NIGMS Mission (R34)
  (PAR-17-268)
  SPONSOR: National Institute of General Medical Sciences
  Application Receipt/Submission Date(s): Multiple dates, see announcement

• TITLE: Tobacco Regulatory Science (R01)
  (RFA-OD-17-007)
  SPONSOR: National Institutes of Health, U.S. Food and Drug Administration, Center for Tobacco Products
National Cancer Institute, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and
Alcoholism, National Institute on Drug Abuse, National Institute of Environmental Health Sciences
  Office of Disease Prevention
  Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support
biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect
public health. Research Projects must address the research priorities related to the regulatory authority of the Food and
Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH
using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control
Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant
in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public
health.
  Application Receipt Date(s): Multiple dates, see announcement
**TITLE:** Tobacco Regulatory Science Small Grant Program for New Investigators (R03)  
(RFA-OD-17-008)  
**SPONSOR:** National Institutes of Health, National Cancer Institute, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, Office of Disease Prevention  
**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to invite R03 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.  
Application Receipt Date(s): Multiple dates, see announcement

**TITLE:** Tobacco Regulatory Science (R21)  
(RFA-OD-17-009)  
**SPONSOR:** National Institutes of Health, National Cancer Institute, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, Office of Disease Prevention  
**Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to invite research project applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.  
Application Receipt Date(s): Multiple dates, see announcement

**TITLE:** Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (U34)  
(RFA-HL-18-008)  
**SPONSOR:** National Heart, Lung, and Blood Institute  
**Application Receipt Date(s):** Multiple dates, see announcement

**TITLE:** Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (X01)  
(RFA-HL-18-009)  
**SPONSOR:** National Heart, Lung, and Blood Institute  
**Application Receipt Date(s):** Multiple dates, see announcement

---

**PROGRAM ANNOUNCEMENTS**

**TITLE:** Leveraging Population-based Cancer Registry Data to Study Health Disparities (R21)  
(PA-17-288)  
**SPONSOR:** National Cancer Institute  
**Synopsis:** The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors influencing observed health disparities within the framework of population-based cancer registries by the inclusion of data not routinely collected by or linked to the registries. The studies should be hypothesis-driven and multidisciplinary approaches are encouraged. Investigators are encouraged to leverage the data already collected by the registries to investigate the determinates of health disparities. The goal of these analyses will be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.  
Application Receipt/Submission Date(s): Multiple dates, see announcement

**TITLE:** Leveraging Population-based Cancer Registry Data to Study Health Disparities (R01)  
(PA-17-289)  
**SPONSOR:** National Cancer Institute  
**Synopsis:** The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors influencing observed health disparities within the framework of population-based cancer registries by the inclusion of data not routinely collected by or linked to the registries. The studies should be hypothesis-driven and multidisciplinary approaches are encouraged. Investigators are encouraged to leverage the data already collected by the registries to investigate the determinates of health disparities. The goal of these analyses will be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.  
Application Receipt/Submission Date(s): Multiple dates, see announcement
persist by identifying factors contributing to disparities and their relative importance.

Application Receipt/Submission Date(s): Multiple dates, see announcement

• **TITLE:** Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans Resource Access (X01) (PAR-17-294)
  **SPONSOR:** National Heart, Lung, and Blood Institute
  Application Receipt/Submission Date(s): Multiple dates, see announcement

**OTHER FUNDING OPPORTUNITIES**
(Sponsors in bold are NIH Peer Reviewed Organizations)

• **TITLE:** AACR Scientific Achievement Awards - Pezcoller Foundation-AACR International Award for Cancer Research
  [http://www.aacr.org/Research/Awards/Pages/Awards-Detail.aspx?Itemld=16#.V1GVeb7tbhR](http://www.aacr.org/Research/Awards/Pages/Awards-Detail.aspx?Itemld=16#.V1GVeb7tbhR)
  **SPONSOR:** American Association for Cancer Research (AACR)
  **Synopsis:** This award was established in 1997 to annually recognize a scientist of international renown:
  - who has made a major scientific discovery in basic cancer research or who has made significant contributions to translational cancer research;
  - who continues to be active in cancer research and has a record of recent, noteworthy publications; and
  - whose ongoing work holds promise for continued substantive contributions to progress in the field of cancer.

• **TITLE:** Grant and Fellowship Program – Fellowships
  **SPONSOR:** Prevent Cancer Foundation
  **Synopsis:** The Prevent Cancer Foundation is the only U.S. 501(c)3 nonprofit organization solely devoted to cancer prevention and early detection. Prevent Cancer focuses its resources on cancers that can be prevented through lifestyle changes or early detection, when treatment is more likely to be successful. Prevent Cancer is devoted to saving lives through cancer prevention and early detection across all populations. Since its founding in 1985, Prevent Cancer has invested more than $138 million in research, education, advocacy and community outreach programs across the nation in support of its mission. Research must be conducted in the United States primarily.
  Proposals must fall within the scope of the Foundation's mission and funding priorities to be considered. The goal of the Foundation's research program is to provide funding for innovative projects expected to lead to future funding from other peer-reviewed sources. Basic science grants must demonstrate substantial potential for impact on prevention or early detection of cancer (specifically, pre-clinical research is acceptable but must be prevention-oriented and clearly identifiable as translational).

• **TITLE:** Lung Cancer Research Program (LCRP): Concept Award
  **SPONSOR:** United States Department of Defense (DOD), Department of the Army, U.S. Army Medical Research and Materiel Command (USAMRMC), Office of Congressionally Directed Medical Research Programs (CDMRP)
  **Synopsis:** The goal of the FY17 LCRP is to eradicate deaths from lung cancer to better the health and welfare of military Service members, Veterans, their families, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer. To be considered for funding, applications for the FY17 LCRP Concept Award must address at least one of the seven Areas of Emphasis listed below:
  - Identify, develop, or optimize noninvasive or minimally invasive tools to improve the detection of the initial stages of lung cancer, such as, but not limited to, optimizing strategies for management of indeterminate nodules.
  - Identify, develop, and/or build upon already existing tools for screening or early detection of lung cancer. Screening may include, but is not limited to, imaging modalities, biomarkers, genomics/proteomics/metabolomics/transcriptomics, and assessment of risk factors.
  - Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
  - Identify innovative strategies for prevention and treatment of early and/or localized lung cancer.
  - Understand predictive and prognostic markers to identify responders and nonresponders.
  - Understand susceptibility or resistance to treatment.
  - Understand contributors to lung cancer development other than tobacco.

• **TITLE:** Grant and Fellowship Program - Grants
  **SPONSOR:** Prevent Cancer Foundation
  **Synopsis:** The Prevent Cancer Foundation is the only U.S. 501(c)3 nonprofit organization solely devoted to cancer prevention and early detection. Prevent Cancer focuses its resources on cancers that can be prevented through lifestyle changes or early detection, when treatment is more likely to be successful. Prevent Cancer is devoted to saving lives through cancer prevention and early detection across all populations. Since its founding in 1985, Prevent Cancer has invested more than $138 million in research, education, advocacy and community outreach programs across the nation in support of its mission.
  Research must be conducted in the United States primarily.
Proposals must fall within the scope of the Foundation’s mission and funding priorities to be considered. The goal of the Foundation’s research program is to provide funding for innovative projects expected to lead to future funding from other peer-reviewed sources. Basic science grants must demonstrate substantial potential for impact on cancer prevention or early detection (specifically, pre-clinical research is acceptable but must be prevention-oriented and clearly identifiable as translational).

- **Title:** Lung Cancer Research Program (LCRP): Career Development Award  
  **Sponsor:** United States Department of Defense (DOD), Department of the Army, U.S. Army Medical Research and Materiel Command (USAMRMC), Office of Congressionally Directed Medical Research Programs (CDMRP)  
  **Synopsis:** The goal of the FY17 LCRP is to eradicate deaths from lung cancer to better the health and welfare of military Service members, Veterans, their families, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer. To be considered for funding, applications for the FY17 LCRP Concept Award must address at least one of the seven Areas of Emphasis listed below:
  - Identify, develop, or optimize noninvasive or minimally invasive tools to improve the detection of the initial stages of lung cancer, such as, but not limited to, optimizing strategies for management of indeterminate nodules.
  - Identify, develop, and/or build upon already existing tools for screening or early detection of lung cancer. Screening may include, but is not limited to, imaging modalities, biomarkers, genetics/genomics/proteomics/metabolomics/transcriptomics, and assessment of risk factors.
  - Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
  - Identify innovative strategies for prevention and treatment of early and/or localized lung cancer.
  - Understand predictive and prognostic markers to identify responders and nonresponders.
  - Understand susceptibility or resistance to treatment.
  - Understand contributors to lung cancer development other than tobacco.

- **Title:** Lung Cancer Research Program (LCRP): Investigator-Initiated Translational Research Award  
  **Sponsor:** United States Department of Defense (DOD), Department of the Army, U.S. Army Medical Research and Materiel Command (USAMRMC), Office of Congressionally Directed Medical Research Programs (CDMRP)  
  **Synopsis:** The goal of the FY17 LCRP is to eradicate deaths from lung cancer to better the health and welfare of military Service members, Veterans, their families, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer. To be considered for funding, applications for the FY17 LCRP Investigator-Initiated Translational Research Award must address at least one of the seven Areas of Emphasis listed below:
  - Identify, develop, or optimize noninvasive or minimally invasive tools to improve the detection of the initial stages of lung cancer, such as, but not limited to, optimizing strategies for management of indeterminate nodules.
  - Identify, develop, and/or build upon already existing tools for screening or early detection of lung cancer. Screening may include, but is not limited to, imaging modalities, biomarkers, genetics/genomics/proteomics/metabolomics/transcriptomics, and assessment of risk factors.
  - Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
  - Identify innovative strategies for prevention and treatment of early and/or localized lung cancer.
  - Understand predictive and prognostic markers to identify responders and nonresponders.
  - Understand susceptibility or resistance to treatment.
  - Understand contributors to lung cancer development other than tobacco.

- **Title:** Lung Cancer Research Program (LCRP): Lung Cancer Research Program (LCRP): Idea Development Award  
  **Sponsor:** United States Department of Defense (DOD), Department of the Army, U.S. Army Medical Research and Materiel Command (USAMRMC), Office of Congressionally Directed Medical Research Programs (CDMRP)  
  **Synopsis:** The goal of the FY17 LCRP is to eradicate deaths from lung cancer to better the health and welfare of military Service members, Veterans, their families, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer. To be considered for funding, applications for the FY17 LCRP Idea Development Award must address at least one of the seven Areas of Emphasis listed below:
  - Identify, develop, or optimize noninvasive or minimally invasive tools to improve the detection of the initial stages of lung cancer, such as, but not limited to, optimizing strategies for management of indeterminate nodules.
  - Identify, develop, and/or build upon already existing tools for screening or early detection of lung cancer. Screening may include, but is not limited to, imaging modalities, biomarkers, genetics/genomics/proteomics/metabolomics/transcriptomics, and assessment of risk factors.
  - Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
  - Identify innovative strategies for prevention and treatment of early and/or localized lung cancer.
  - Understand predictive and prognostic markers to identify responders and nonresponders.
  - Understand susceptibility or resistance to treatment.
- Understand contributors to lung cancer development other than tobacco.

**TITLE:** Career Catalyst Research (CCR) Grants  
[http://ww5.komen.org/ResearchGrants/FundingOpportunities.html](http://ww5.komen.org/ResearchGrants/FundingOpportunities.html)  
**SPONSOR:** Susan G. Komen  
**Synopsis:** Career Catalyst Research (CCR) Grants are intended to foster promising breast cancer researchers who are in the early stages of their faculty careers by providing support for up to three years of "protected time" for research career development under the guidance of a Mentor Committee. It is expected that following the successful completion of a CCR Grant, awardees will launch independent research careers, successfully compete for subsequent research project funding, and emerge as key leaders in the fight against breast cancer. The goal of the FY18 CCR Grant is to support outstanding translational research focused on those breast cancers that do not currently respond well to standard of care therapies including triple negative breast cancer (TNBC), ER+ breast cancer with acquired resistance, and metastatic breast cancer of all sub-types.

**TITLE:** Independent Grants for Learning & Change: Request for Proposals (RFP) - Clinical Pathways in Breast Cancer  
**SPONSOR:** Pfizer, Inc.

**TITLE:** Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01)  
**Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R21)**  
**SPONSOR:** United States Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI)  
**Synopsis:** This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of exosomes as well as the computational analysis of the cargo carried in these vesicles.

**TITLE:** Lung Cancer Research Program (LCRP) Translational Research Partnership Award  
**SPONSOR:** United States Department of Defense (DOD), Department of the Army, U.S. Army Medical Research and Materiel Command (USAMRMC), Office of Congressionally Directed Medical Research Programs (CDMRP)  
**Synopsis:** The FY17 LCRP Translational Research Partnership Award mechanism supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications. This award supports the development of translational research collaborations between two independent, faculty level (or equivalent) investigators to address a central problem or question in lung cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. In addition, one partner in the collaboration is strongly encouraged to be an active duty Service member or Federal employee from a military treatment facility, Department of Defense (DoD) laboratory, or a Department of Veterans Affairs (VA) medical center or research laboratory. It should be clear that both have had equal intellectual input into the design of the research project. Multi-institutional partnerships are encouraged but not required. At least one member of the partnership must have experience either in lung cancer research or lung cancer patient care. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician's firsthand knowledge of patients and anecdotal data. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, members of the partnership should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science.

**TITLE:** NIH Support for Conferences and Scientific Meetings (Parent R13)  
**SPONSOR:** United States Department of Health and Human Services (HHS), National Institutes of Health (NIH)  
**Synopsis:** The purpose of the NIH Research Conference (R13) Grant and NIH Research Conference Cooperative Agreement (U13) Programs is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.

**TITLE:** Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)  
**SPONSOR:** United States Department of Health and Human Services (HHS)National Institutes of Health (NIH)  
**Synopsis:** The purpose of the Kirschstein-NRSA predoctoral fellowship (F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the applicant's dissertation research
project and is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist.

- **TITLE:** Ruth L. Kirschstein National Research Service Award (NRSA) Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

**SPONSOR:** United States Department of Health and Human Services (HHS) National Institutes of Health (NIH)

**Synopsis:** This Funding Opportunity Announcement (FOA) will support students at institutions without formal NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Applicants must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individuals' potential to develop into a productive, independent physician/clinician-scientist.

- **TITLE:** Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Postdoctoral Fellows (Parent F32)

**SPONSOR:** United States Department of Health and Human Services (HHS) National Institutes of Health (NIH)

**Synopsis:** The purpose of the Kirschstein-NRSA postdoctoral fellowship is to enhance the research training of promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers.